Asher Biotherapeuticsannounced that it has entered into a clinical trial collaboration and supply agreement with Merck for a planned Phase Ia/Ib dose escalation and expansion trial to evaluate AB248, Asher Bio’s novel investigational CD8-targeted interleukin 2.
[Asher Biotherapeutics]
